Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline versus dienogest for pain reduction in endometriosis
IRCT20181030041503N6Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cabergoline and dienogest in endometriosis (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Endometriosis-associated pain score and Dysmenorrhea pain severity. Started Dec 2022; status: completed.
02
Drugs
cabergolinedienogest
03
Conditions
endometriosis
Beyond the preview
Go deeper on IRCT20181030041503N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181030041503N6.